更新于：2024-06-22
Tirofiban Hydrochloride
盐酸替罗非班
更新于：2024-06-22
概要
基本信息
药物类型 小分子化药 |
别名 (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid、N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine、Tirfiban Hydrichloride + [16] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C22H39ClN2O6S |
InChIKeyHWAAPJPFZPHHBC-FGJQBABTSA-N |
CAS号150915-40-5 |
关联
78
项与 盐酸替罗非班 相关的临床试验Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Safety and Efficacy of Adjunct Tirofiban Treatment After Successful Mechanical Thrombectomy Recanalization in Acute Anterior Circulation Ischemic Stroke- A Multicenter, Prospective, Double-blind, Randomized Trial
Prophylactic Administration of Tirofiban for Preventing Thromboembolic Events in Stent-assisted Coiling and Flow Diversion Treatments of Unruptured Intracranial Aneurysms
100 项与 盐酸替罗非班 相关的临床结果
登录后查看更多信息
100 项与 盐酸替罗非班 相关的转化医学
登录后查看更多信息
100 项与 盐酸替罗非班 相关的专利（医药）
登录后查看更多信息
1,515
项与 盐酸替罗非班 相关的文献（医药）2024-04-01The neuroradiology journal
Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis
Review
作者: Keykhosravi, Ehsan ; Maleki, Samane ; Abbasi Shaye, Zahra ; Rezaee, Hamid ; Hasanpour, Mohammad ; Aminzadeh, Behzad
Background and Aims:
Thromboembolism complication is considered the most common complication associated with the treatment of endovascular. This systematic review and meta-analysis aimed to assess the studies investigating the effect of glycoprotein IIb/IIIa inhibitor agents on thromboembolic complications during endovascular aneurysm coiling.
Materials and Methods:
This systematic review investigated the outcome of the use of three glycoprotein IIb/IIIa inhibitor agents (ie abciximab, tirofiban, and eptifibatide) on the thromboembolic complications during endovascular aneurysm coiling. The electronic databases of PubMed, Web of Science, Scopus, and Medline were searched up to 25 June 2021, using the keywords “Abciximab,” “Tirofiban,” and “Eptifibatide” incombination with “Thromboembolism Complication,” “Aneurysms,” and “Endovascular Aneurysm Coiling.”
Results:
A total of 21 articles were found to be eligible and included in this review. The rates of complete and partial recanalization were estimated to be 56% and 92% in patients who underwent abciximab and tirofiban therapy, respectively. Rupture aneurysms were found in the majority of patients. In general, the mortality rate of the patients treated for thromboembolic complications during endovascular treatment of cerebral aneurysms with glycoprotein IIb/IIIa inhibitors was found to be 4.8% (CI 95%:0.027–0.067; p < .005). The average remission rate in studies investigating thromboembolism was 91% (CI 95%:0.88–0.95, I2 : 65.65/ p < .001).
Conclusion:
Based on the obtained results, a higher mean rate of complete recanalization by eptifibatide was found in studies in which abciximab or tirofiban were used, compared to other mentioned agents. Moreover, the amount of hemorrhage was reported to be less after using tirofiban rather than abciximab.
2024-03-01Clinical neuroradiology
Efficacy and Safety Outcomes for Acute Ischemic Stroke Patients Treated with Intravenous Infusion of Tirofiban After Emergent Carotid Artery Stenting
Article
作者: Ertl, Michael ; Schneider, Hauke ; Schiele, Stefan ; Müller, Gernot ; Berlis, Ansgar ; Garayzade, Rana ; Maurer, Christoph J
Abstract:
Introduction:
Emergent stenting of the extracranial internal carotid artery (ICA) in stroke patients requires antiplatelet therapy to prevent in-stent thrombosis with a higher risk of intracranial haemorrhage.
Aim of the Study:
Assess the efficacy and safety of emergent carotid stenting with intravenous tirofiban in acute ischemic stroke patients.
Methods:
Primary endpoint: symptomatic hemorrhage. Secondary endpoints: 90-day functional outcome and mortality.
Results:
Of the 62 patients, 21 (34%) received tirofiban as a single antiplatelet, and 41 (66%) received combined therapy. Premedication with anticoagulants and antiplatelets was significantly more frequent in the tirofiban-only group. The rate of symptomatic haemorrhage was significantly lower in the tirofiban-only group than in the combined group (4.8% vs. 27%, p = 0.046). The patients with tirofiban alone had a significantly better functional outcome at day 90 than the combined group (52% vs. 24%, p = 0.028). Mortality was equal (24%) in both groups. Pre-interventional NIHSS score (p = 0.003), significant blood pressure fluctuations (p = 0.012), tandem occlusion (p = 0.023), and thrombolysis (p = 0.044) showed relevant influence on the rate of symptomatic hemorrhage in the entire patient cohort.
Conclusions:
A single antiplatelet therapy with tirofiban regardless of the premedication may improve the functional outcome in patients with stroke due to acute extracranial carotid lesion and emergent carotid stenting with lower rates of serious intracranial haemorrhage.For patients with high pre-interventional NIHSS score, tandem occlusion and after pre-interventional thrombolysis, caution is advised. Additionally, strict blood pressure monitoring should be conducted during the first 72 h after intervention.
2024-03-01Annals of clinical and translational neurology
Effects of tirofiban on large vessel occlusion stroke are modified by etiology and renal function
Article
作者: Qiu, Zhongming ; Nguyen, Thanh N ; Kong, Weiling ; Pan, Yanzhu ; Chen, Liyuan ; Abdalkader, Mohamad ; Sang, Hongfei ; Liu, Chang ; Huang, Jiacheng ; Guo, Changwei ; Huang, Liping ; Li, Fengli ; Chen, Yangmei ; Zi, Wenjie ; Yang, Jie ; Saver, Jeffrey L ; Wang, Xinxin ; Gong, Chen
Abstract:
Objective:
Renal function can modify the outcomes of large vessel occlusion (LVO) stroke across stroke etiologies in disparate degrees. The presence of renal function deficit can also impair the pharmacokinetics of tirofiban. Hence, this study aimed to investigate the roles of renal function in determining efficacy and safety of intravenous tirofiban before endovascular treatment (EVT) for acute ischemic stroke patients with large vessel occlusion (LVO).
Methods:
This study was a post hoc exploratory analysis of the RESCUE‐BT trial. The primary outcome was the proportion of patients achieving functional independence (modified Rankin scale 0–2) at 90 days, and the primary safety outcome was the rate of symptomatic intracranial hemorrhage (sICH).
Results:
Among 908 individuals with available serum creatinine, decreased estimated glomerular filtration rate (eGFR) status was noted more commonly in patients with cardioembolic stroke (CE), while large artery atherosclerosis (LAA) was predominant in patients with normal renal function. In LAA with normal renal function, tirofiban was associated with higher rates of functional independence at 90 days (41.67% vs 59.80%, p = 0.003). However, for LVO patients with renal dysfunction, tirofiban did not improve functional outcomes for any of the etiologies (LAA, p = 0.876; CE, p = 0.662; others, p = 0.894) and significantly increased the risk of sICH among non‐LAA patients (p = 0.020). Mediation analysis showed tirofiban reduced thrombectomy passes (12.27%) and drug/placebo to recanalization time (14.25%) mediated its effects on functional independence.
Conclusion:
This present study demonstrated the importance of evaluating renal function before administering intravenous tirofiban among patients with LVO who are planned to undergo EVT.
100 项与 盐酸替罗非班 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非 ST 段抬高急性冠脉综合征 | 美国 | 2013-10-10 | |
| 不稳定型心绞痛 | 中国 | 2003-06-13 | |
| 心肌梗塞 | 中国 | 2003-06-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 425 | Intravenous Tirofiban | 窪鹹廠壓遞齋鏇鑰獵觸(鑰獵鹽構鑰鬱糧廠壓夢) = 鹹蓋鏇齋憲膚遞襯襯製 壓淵積壓製範鏇膚壓膚 (選蓋艱觸窪鬱選繭鹹膚 ) | 积极 | 2024-04-22 | ||
Oral Aspirin | 窪鹹廠壓遞齋鏇鑰獵觸(鑰獵鹽構鑰鬱糧廠壓夢) = 構積膚顧衊積選網顧範 壓淵積壓製範鏇膚壓膚 (選蓋艱觸窪鬱選繭鹹膚 ) | ||||||
N/A | - | Tirofiban plus EVT | 膚選鹽鏇積餘窪築醖壓(網醖積廠鹹築網廠網製) = 襯範鹹餘廠鑰夢衊襯鑰 鹽淵憲網構憲蓋糧艱願 (糧膚淵糧願蓋積襯觸廠 ) | - | 2024-04-01 | ||
Alteplase bridging with EVT | 膚選鹽鏇積餘窪築醖壓(網醖積廠鹹築網廠網製) = 糧廠襯襯遞壓簾願製築 鹽淵憲網構憲蓋糧艱願 (糧膚淵糧願蓋積襯觸廠 ) | ||||||
N/A | 406 | 簾膚廠觸願鏇窪願築鹹(齋遞糧鹽蓋窪簾築鏇夢): aOR = 0.91 (95% CI, 0.64 ~ 1.3), P-Value = 0.617 更多 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 467 | EVT-alone | 廠衊壓鹽醖網餘壓壓廠(鏇鏇壓遞廠醖糧顧鏇醖): adjusted RR = 1.12 (95% CI, 0.92 ~ 1.36), P-Value = 0.27 | - | 2023-02-01 | ||
tirofiban+EVT | |||||||
N/A | 950 | 膚齋齋築蓋窪網鹽衊範(膚鏇鹹願遞餘襯獵構範): common OR = 1.74 (95% CI, 1.14 ~ 2.65), P-Value = 0.01 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 417 | 鬱願艱鑰觸膚鏇繭觸淵(製膚鹹鹽獵範觸蓋壓繭): adjusted risk ratio = 1.17 (95% CI, 1.05 ~ 1.31) 更多 | 积极 | 2023-02-01 | |||
N/A | 926 | 艱鏇簾醖範衊遞遞衊繭(鏇製築醖夢蓋壓糧觸鹽): Risk Ratio = 1.24 (95% CI, 1.02 ~ 1.52) | - | 2023-02-01 | |||
Placebo | |||||||
临床4期 | 948 | 鑰網淵構夢鬱餘積獵齋(襯衊窪範遞淵廠繭選壓) = 顧簾窪齋範鬱遞選簾製 鹽壓選鬱襯醖廠衊網鏇 (顧鹹鹹範糧鬱簾糧繭膚 ) 更多 | 不佳 | 2022-08-09 | |||
Placebo | 鑰網淵構夢鬱餘積獵齋(襯衊窪範遞淵廠繭選壓) = 網壓鏇窪蓋築築艱衊壓 鹽壓選鬱襯醖廠衊網鏇 (顧鹹鹹範糧鬱簾糧繭膚 ) 更多 | ||||||
临床1/2期 | 30 | 觸窪積鑰餘淵糧憲膚膚(網糧繭製鬱廠蓋襯醖鏇) = 齋獵憲顧構夢網鹹遞壓 糧構鑰繭繭顧鹽鏇夢醖 (遞築獵獵醖繭繭膚蓋繭 ) 更多 | 积极 | 2021-12-01 | |||
Placebo | 觸窪積鑰餘淵糧憲膚膚(網糧繭製鬱廠蓋襯醖鏇) = 願選壓淵壓窪網範製壓 糧構鑰繭繭顧鹽鏇夢醖 (遞築獵獵醖繭繭膚蓋繭 ) 更多 | ||||||
临床1/2期 | 30 | Questionnaires+tirofiban hydrochloride (AGGRASTAT®) (Tirofiban Hydrochloride (AGGRASTAT®)) | 遞窪鹹鬱窪築齋淵餘艱(蓋範艱壓窪鹹選衊廠艱) = 鬱糧廠醖醖鏇觸遞獵壓 齋網積選鹹鹽範夢鬱膚 (壓選蓋憲憲積顧憲憲憲, 鑰蓋齋餘觸簾積鹽積網 ~ 遞顧遞鏇窪鬱觸願觸艱) 更多 | - | 2021-10-04 | ||
Standard of Care Treatment (Standard of Care Control Arm) | 遞窪鹹鬱窪築齋淵餘艱(蓋範艱壓窪鹹選衊廠艱) = 壓鬱餘壓醖襯鹹夢糧遞 齋網積選鹹鹽範夢鬱膚 (壓選蓋憲憲積顧憲憲憲, 鏇壓獵觸網顧廠鏇觸構 ~ 衊簾艱壓壓醖衊選範壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用